Literature DB >> 10385507

Thrombin-induced platelet activation is inhibited by high- and low-molecular-weight heparin.

E De Candia1, R De Cristofaro, R Landolfi.   

Abstract

BACKGROUND: Thrombin binds to platelet glycoprotein Ib (Gp Ib), and this interaction contributes to platelet activation. Thrombin ligation to Gp Ib was recently shown to be inhibited by heparin, thus raising the hypothesis, investigated in this article, that heparin might inhibit thrombin-induced platelet activation. METHODS AND
RESULTS: Aggregation of gel-filtered platelets by 1 nmol/L thrombin was reduced by both high-molecular-weight (MW) (14 500-Da) and low-MW (4500-Da) heparin, with IC50 values of 1.65+/-0.26 and 5.13+/-0.8 micromol/L, respectively. Homogeneous-MW fractions (16 000- to 13 000-Da range) were used to evaluate the heparin effect on intracytoplasmic calcium release by thrombin. Calcium mobilization by 1 nmol/L thrombin was reduced as a function of heparin concentration, and the inhibitory effect was correlated to the MW of heparin fractions (IC50 values were 1.9+/-0.39, 6.07+/-0.83, and 14. 8+/-0.43 micromol/L for 16 000-, 9000-, and 3000-Da heparin, respectively). Platelet aggregation and calcium mobilization by ADP and by the thrombin receptor-activating peptide were not affected by heparin. The activation of Gp Ib-depleted platelets by alpha-thrombin was not inhibited by heparin. Moreover, platelet stimulation by heparin binding site phosphopyridoxylated thrombin, which has a severe impairment of Gp Ib ligation, was not affected by heparin. Finally, heparin did not interfere with the hydrolysis by thrombin of the protease-activated receptor 1.
CONCLUSIONS: These results demonstrated that heparin, by inhibiting the thrombin-Gp Ib interaction, is able to interfere with thrombin-induced platelet activation. The extent of the inhibitory effect is directly related to the MW of heparin fractions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10385507     DOI: 10.1161/01.cir.99.25.3308

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  10 in total

1.  Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome.

Authors:  Richard C Becker; Kenneth W Mahaffey; Hongqiu Yang; A J Marian; Mark I Furman; A Michael Lincoff; Stanley L Hazen; John L Petersen; Craig J Reist; Neal S Kleiman
Journal:  J Thromb Thrombolysis       Date:  2011-02       Impact factor: 2.300

2.  Thrombin-induced conversion of fibrinogen to fibrin results in rapid platelet trapping which is not dependent on platelet activation or GPIb.

Authors:  Gavin E Jarvis; Ben T Atkinson; Jon Frampton; Steve P Watson
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

3.  Low anticoagulant heparin blocks thrombin-induced endothelial permeability in a PAR-dependent manner.

Authors:  Joyce N Gonzales; Kyung-mi Kim; Marina A Zemskova; Ruslan Rafikov; Brenten Heeke; Matthew N Varn; Stephen Black; Thomas P Kennedy; Alexander D Verin; Evgeny A Zemskov
Journal:  Vascul Pharmacol       Date:  2014-01-25       Impact factor: 5.773

4.  Isolation and characterization of a heparin with low antithrombin activity from the body of Styela plicata (Chordata-Tunicata). Distinct effects on venous and arterial models of thrombosis.

Authors:  Joana C Santos; Juliana M F Mesquita; Celso L R Belmiro; Carolina B M da Silveira; Christian Viskov; Pierre A Mourier; Mauro S G Pavão
Journal:  Thromb Res       Date:  2007-05-04       Impact factor: 3.944

Review 5.  Thrombin domains: structure, function and interaction with platelet receptors.

Authors:  Raimondo De Cristofaro; Erica De Candia
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

6.  Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention.

Authors:  J R S Day; I S Malik; A Weerasinghe; M Poullis; I Nadra; D O Haskard; K M Taylor; R C Landis
Journal:  Heart       Date:  2004-07       Impact factor: 5.994

Review 7.  Marine polysaccharides from algae with potential biomedical applications.

Authors:  Maria Filomena de Jesus Raposo; Alcina Maria Bernardo de Morais; Rui Manuel Santos Costa de Morais
Journal:  Mar Drugs       Date:  2015-05-15       Impact factor: 5.118

8.  GpIbα interacts exclusively with exosite II of thrombin.

Authors:  Bernhard C Lechtenberg; Stefan M V Freund; James A Huntington
Journal:  J Mol Biol       Date:  2013-12-05       Impact factor: 5.469

9.  Antiplatelet therapy for patients with COVID-19: Systematic review and meta-analysis of observational studies and randomized controlled trials.

Authors:  Xiaolong Zong; Xiao Wang; Yaru Liu; Zhenyu Li; Weiding Wang; Dianjun Wei; Zhuqing Chen
Journal:  Front Med (Lausanne)       Date:  2022-09-07

Review 10.  Heparin: an intervenor in cell communication.

Authors:  Xianxiang Xu; Yue Dai
Journal:  J Cell Mol Med       Date:  2009-07-31       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.